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Abstract
The prevalence of Diabetes Mellitus is increasing
worldwide. In developing countries 25% of adult females
with diabetes are in the reproductive age. Thus in
developing countries increased number of pregnancies
are complicated by diabetes. Uncontrolled diabetes in
pregnancy is associated with increased risk for both
mother and foetus. These risks can be minimized by good
control of diabetes before and during pregnancy.
Management in the preconception period is discussed in
this review article. Detailed management involves
general advice of lifestyle modification followed by
specific details of screening for complications of
diabetes. Changes in the drugs for both glycaemic
control and other co-morbid conditions are discussed.
The recommended insulin regimen in the preconception
period and monitoring of glycaemic control by self-
monitoring of blood glucose (SMBG) and HbA1C has also
been highlighted.
Keywords: Preconception, Diabetes mellitus, Glycaemic
control, Pregnancy.
Introduction
The prevalence of Diabetes Mellitus continues to rise
worldwide. International Diabetes Federation predicts a
55% increase in diabetes prevalence by 2040. In
developed world more than 50% of diabetics are above
the age of 65 and only 8% of adults are less than 44 years
of age, the childbearing age. In contrast in developing
countries 25% of adults with diabetes are in the
reproductive age.1
Thus in developing countries increased number of
pregnancies are complicated by diabetes.
Risks associated with diabetes during
pregnancy
Pregnancies of women with diabetes are regarded as high
risk for both mother and foetus. Miscarriage/abortion,
pre-eclampsia and pre-term labour is more common in
women with preexisting diabetes.2 The rate of caesarian
section is also higher in diabetic pregnancies. Diabetic
retinopathy3 and possibly diabetic nephropathy4 may
also worsen during pregnancy. Congenital malformations,
macrosomia, birth injury, perinatal mortality and
postnatal hypoglycaemia are more common in babies
born to mothers with preexisting diabetes. These risks can
be minimized by good control of diabetes before and
during pregnancy.5
Management in the pre conception period
Almost all guidelines recommend a multi-disciplinary
approach in diabetic patients who are contemplating
pregnancy. They should be counseled about the
importance of strict glycaemic control prior to
conception. This should be achieved by informing the
women that foetal organogenesis occurs during the first 7
weeks of intrauterine life some of which occurs before
missing the first menstrual period emphasizing the
importance of a planned pregnancy.
Diabetic women with an HbA1C >8% should be
discouraged from becoming pregnant. Strongly advise
women with HbA1C >10% not to get pregnant.
Spontaneous miscarriages and foetal malformations are
low when the HbA1C is modestly raised and increases
rapidly with higher HbA1C levels (Figure).
The possibility of pregnancy should be identified by direct
questioning at each clinic visit in all women of child -
bearing age with diabetes.
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Contraception
Contraception should be recommended until optimal
diabetic control has been achieved. The contraception
methods are the same as in the general population but in
the presence of vascular complications, estrogen
containing contraceptive pills should be avoided.7
Health Promotion in the pre conception
period
Women planning to conceive should be encouraged to
stop smoking after discussing consequences of smoking
during pregnancy.
They should also be asked to stop alcohol consumption.
BMI should be calculated and if overweight or obese
weight reduction prior to conception should be
discussed. Obesity is an independent risk factor for delay
in conception and for foetal abnormalities and adverse
pregnancy outcomes.6
Folic acid supplementation is advised for at least three
months before conception and to be continued for up to
3 months after conception.9 Other nutrient
supplementation like iron, calcium and vitamin D should
also be considered particularly in the developing world.
Dietary advice in the pre conception period
Intrauterine growth and development are dependent
upon adequate nutrition throughout pregnancy.
Extremes of birth weight have long-term consequences.
Dietary advice should be appropriate with personal needs
and culturally acceptable. Carbohydrate monitoring
remains the key aspect in achieving glycaemic control. A
balanced diet which includes fruits, vegetables, whole
grain, legumes and milk is recommended for good health.
Physical activity in the pre conception period
Physical activity is encouraged because it has beneficial
effects on insulin resistance in type 2 diabetic patients.
Women on insulin regimen management of
hypoglycaemia resulting from physical activity should be
discussed and appropriately prevented.
Screening for Diabetic Complications
All diabetic women planning pregnancy should be
screened for complications of diabetes, as these may
accelerate during pregnancy and may change the
outcome of pregnancy. In the case of advanced
complications, specialist opinion should be sought from a
diabetologist/endocrinologist with special interest in
diabetes in pregnancy. A complete medical and
obstetrical history should be obtained.
Retinal Assessment
Retinal assessment should be done by a diabetologist,
ophthalmologist or using a digital camera with mydriasis
using tropicamide unless they have had an annual
assessment in the last six months.7 The women who are
contemplating pregnancy should be advised to defer
rapid optimization of their diabetes until retinal
assessment and treatment has been completed. There is a
risk of progression of retinopathy during pregnancy
which can be reduced through gradual improvement in
glycaemic control rather than aggressive approach.
Renal assessment
Renal assessment should also be done by measuring
serum creatinine, estimating e-GFR and measuring urine
micro albumin. If serum creatinine is raised, e-GFR is less
than 45 ml/minute or urinary albumin creatinine ratio is
greater than 30 mg/mmol, consider referring to a
nephrologist before going ahead with conception.7 In the
presence of overt diabetic nephropathy there is increased
risk of permanent deterioration in maternal renal function
and poor obstetric outcomes. In less severe diabetic
nephropathy there is a risk of transient deterioration of
renal function during pregnancy.
Cardiovascular assessment
Blood Pressure should be monitored at the initial
assessment and anti-hypertensives appropriate to the
pregnancy should be prescribed.
Coronary artery disease if untreated is associated with
high maternal mortality during pregnancy. Preexisting
coronary artery disease needs assessment and
optimization of medications by the cardiologist prior to
conception.
Thyroid function assessment
Thyroid function test should be assessed in all type 1
diabetics prior to conception and also in all patients
known to have thyroid disorders both hypothyroidism
and hyperthyroidism.
Glucose lowering agents in pre conception
period and during pregnancy
Insulin remains the agent of choice for use in the pre
conception period and during pregnancy. Metformin has
been extensively studied in pregnancy. Metformin does
not cross the placenta and there appears to be no
teratogenic effects of this drug.
Among the sulphonylureas, glyburide/glibenclamide has
been studied. It was considered safe until recently when
some reports of adverse outcomes of using this drug in
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3rd trimester has appeared. National Institute for Health
and Care Excellence (NICE),7 Canadian Diabetes
Association (CDA)[9] and other bodies suggest that
metformin may be used alone or as an adjunct to insulin
in the pre conception period. All other oral and parenteral
anti-diabetic agents should be discontinued before
pregnancy and should be substituted by insulin.
Short acting human insulin and rapid acting insulin
analogues (Aspart and Humalog) have been proven safe
during pregnancy and are categorized as category B for
pregnancy. Isophane insulin (NPH) and long acting insulin
analogue Detemir is also a category B drug for pregnancy
and can be safely used. Consider continuing long acting
insulin analogue glargine (category C) in women with
diabetes who have established good control of diabetes
before pregnancy on it.
Glucose control is better achieved when using insulin
regimen that mimics normal physiology. Basal bolus
regimen also called multiple daily insulin (MDI) regimen, a
combination of long acting and rapid acting insulin is the
preferred regimen. Basal bolus regimen allows for
flexibility as regards dose and timing of insulin. Thus it
facilitates achievement of glucose targets, less
hypoglycaemia and less basal insulin limiting excessive
weight gain. Women on pre mixed insulin regimen should
be shifted to basal bolus regimen preferably in the pre
conception period. Subcutaneous insulin infusion (SCII) in
type 1 diabetic patients if started earlier is recommended
to be continued in the pre conception period and during
pregnancy.
Drugs used in diabetes for co morbid
conditions and complications
Anti-hypertensives
Angiotensin converting enzyme inhibitors and
angiotensin receptor blockers/antagonist should be
discontinued before conception. In a large cohort study of
pregnancy ACE inhibitors use in the 1st trimester was
associated with an increased risk of major congenital
malformations.
Calcium channel blockers have the potential to cause
foetal hypoxia and should be used with caution.10
These anti-hypertensives should be stopped in the pre
conception period and replaced with drugs like
methydopa, labetolol, diltiazem, clonidine and prazosin.
Lipid lowering drugs
Statins should be discontinued before pregnancy.
Congenital malformation has been reported with statins
and there is also concern that decreased cholesterol
synthesis may affect foetal development.11 The data on
the use of Niacin and Fibrates during pregnancy is very
limited so it should be stopped in the pre conception
period.
Monitoring of glycaemic control during the
pre-conception period
HbA1C should preferably be done monthly in the pre
conception period. International Diabetes Federation
(IDF) recommends best possible glycaemic control before
pregnancy aiming for an HbA1C of < 6.5% or < 7% if on
insulin.10 American Diabetic Association (ADA) suggests
an HbA1C target of < 7% prior to conception to minimize
risk.12
Self-monitoring of blood glucose (SMBG) is essential with
a mixture of fasting levels, pre meals and post meals.
Ketone testing should be offered to type 1 diabetics who
are planning conception. Ketone testing is recommended
during hyperglycaemia and during periods of illness.
The target of blood glucose levels should be
individualized but generally in patients with preexisting
type 1 or type 2 diabetes, the pre meal glucose should be
less than 90 mg/dl and two hour post meal less than 120
mg/dl. These are glycaemic targets during pregnancy and
efforts should be made to attain them before pregnancy.
Hypoglycaemia risk is increased with tight control of
diabetes so the management of hypoglycaemia should
be comprehensively discussed including glucagon
injections in case of severe hypoglycaemia in home
setting.
Conclusion
Pre-conception optimization of glycaemic control in
diabetics is essential to minimize the risk associated with
uncontrolled diabetes to the mother and foetus. This
involves general health promotion, lifestyle modification
and screening for diabetic complications of retinopathy
and nephropathy. Medications used for diabetes
management are changed to insulin preferably using
basal bolus regimen. Monitoring of diabetes control is
much more intensive with tighter goals of blood glucose
levels and HbA1C.
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